New data from Cognito Therapeutics has indicated that its Spectris device increases cerebrospinal fluid (CSF) HDL-like lipid transport particles, suggesting the neuromodulation therapy prompts a ...
CAMBRIDGE, Mass., July 13, 2026--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company developing novel therapies for neurodegenerative disorders, today announced the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication of a study in ...
Partnership seeks to establish a first-of-its-kind statewide platform for brain health innovation, research, and care PROVIDENCE, R.I., Oct. 13, 2026 /PRNewswire/ -- The Rhode Island Life Science Hub ...
Cognito Therapeutics Presents Exploratory Biomarker Data at AAIC 2026 Supporting Coordinated Modulation of Lipid Transport and Myelination Pathways Unbiased cerebrospinal fluid proteomics identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results